2011 7th Annual Personalized Medicine Conference

Please click on the links below for more information.

 

Overview

 
Welcome to the 2011 Personalized Medicine Conference. The members of the Conference Organizing Committee are pleased to offer this seventh annual gathering co-hosted by Partners HealthCare, Harvard Medical School and Harvard Business School. We offer our profound thanks to the speakers, the panelists, the staff and our generous supporters for their essential contributions.
 
As has been the case since this Conference was inaugurated, we are especially proud to work with the Personalized Medicine Coalition and to have its valuable perspective on the program and its contents. We are also pleased that the PMC has chosen this venue to annually honor an individual with its Award for Leadership in Personalized Medicine. This series of meetings was initiated in 2005 with the firm belief that Personalized Medicine would play an important role in health care. There were many skeptics at that time who believed that personalized medicine was a promise rather than a reality. To a degree some of that skepticism remains. We believe, however, that there are several indications that important strides have been made. The genetic and genomic understanding of health and disease is improving at a rapid pace, fueled by the ever lower cost of DNA sequencing and other technologies; many pharmaceutical and biotechnology companies have embraced personalized medicine as an important tool in drug development; and investments in molecular diagnostics and healthcare services are on the rise. There now are many national scientific, medical and business meetings with their theme as Personalized Medicine. We believe that continued conversations about the current status of this field, its opportunities for improving the health care of human populations without cost increases and the obstacles that face this endeavor are worthy. We have always felt that to promote personalized medicine there needs to be a common forum for physicians, scientists, businesses, investment community, payers, regulators policy makers and the general public. This seventh annual meeting, like its predecessors, hopes to provide such a forum.
 
Our goal for the meeting is to provide information about personalized medicine and engage the audience in intensive discussions about the various topics. We also hope that the meeting provides an opportunity for attendees to renew friendships, convert acquaintances to friends and to meet new people whose knowledge will enhance your own understanding of personalized medicine. We welcome you to this meeting and hope that it will be enjoyable and productive.

Program

 

Conference Program     Wednesday, November 9, 2011
 
7:00 a.m.
 
Registration & Continental Breakfast
 
 
8:00 a.m.
 
Welcome
 
 
 
Opening Remarks
Raju Kucherlapati, Ph.D.
Paul C. Cabot Professor of Genetics, Professor of Medicine, Harvard Medical School
 
Scott Weiss, M.D., M.S.
Scientific Director, Partners HealthCare Center for Personalized Genetic Medicine; Associate Director, Channing Laboratory; Professor of Medicine, Harvard Medical School
 
Dennis Ausiello, M.D.
Jackson Professor of Clinical Medicine, Harvard Medical School; Chief of Medicine, Massachusetts General Hospital; Chief Scientific Officer, Partners HealthCare
 
8:30 a.m.
 
Keynote: Is Personalized Medicine a Myth?
 
Dr. Emanuel recently joined the University of Pennsylvania. He is a bioethicist and formerly worked at the NIH and as a special advisor to the White House Office of Management and Budget. He will present his rationale as a skeptic of personalized medicine and will discuss the landscape of health care and where personalized medicine fits into it.
 
 
 
 
Ezekiel Emanuel, M.D., Ph.D.
Vice Provost for Global Initiatives, Diane v.S. Levy and Robert M. Levy University Professor and Chair of the Department of Medical Ethics and Health Policy, University of Pennsylvania
 
Introducer: Gregory Downing, Ph.D.
Program Director, Personalized Health Care Initiative, The U.S. Department of Health and Human Services
 
9:00 a.m.
New Health Care Models for Personalized Medicine
 
Several leading medical centers are actively developing plans to implement personalized medicine into their research and medical care. Representatives from two such major centers will discuss how their respective institutions made a decision to make personalized medicine an important component of their medical practice and how they are implementing the principles of personalized medicine. 
 
Moderator: Anna Barker, Ph.D.
Professor and Director, Transformative Healthcare Networks, Co-Director, Complex Adaptive Systems Initiative, Arizona State University
 
John Mendelsohn, M.D.
Past President, Co-Director of the Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center
 
John E. Niederhuber, M.D.
Professor of Oncology & Surgery, Johns Hopkins University School of Medicine; Former Director of the National Cancer Institute; Executive VP, Inova Health System; CEO, Inova Translational Medicine Institute
 
9:45 a.m.
Networking Break
 
 
 
10:30 a.m.
The Business of Personalized Medicine: A Panel Discussion
 
For personalized medicine to be successful, appropriate businesses have to embrace it. A number of different types of businesses, large and small, are offering goods and services relating to personalized medicine. This panel will discuss how such services are being or may be offered. Such businesses are also attracting the attention of Wall Street analysts, that perspective will be a part of the conversation. 
 
Moderator: M. Kathleen Behrens Wilsey, Ph.D.
Founder, KEW Group, LLC
 
David King
President and CEO, LabCorp
 
Stephen Little, Ph.D.
Vice President, Personalized Healthcare, QIAGEN
 
Jonathan Sheldon, Ph.D.
Senior Director, Translational Medicine, Oracle Health Sciences Global Business Unit
 
Amanda Murphy, CFA
Healthcare Analyst, Healthcare Research, William Blair & Company
 
11:45 a.m.
Presentation of Personalized Medicine Coalition’s Seventh Annual Award for Leadership in Personalized Medicine
 
Award Recipient: Leroy Hood, M.D., Ph.D.
President and Co-Founder, Institute for Systems Biology
 
Introducer: Edward Abrahams, Ph.D.
President, Personalized Medicine Coalition
 
Presenter: William S. Dalton, Ph.D., M.D.
President, CEO & Center Director, Moffitt Cancer Center
 
12:15 p.m.
 
Luncheon
 
Open seating
 
1:15 p.m.
Keynote
 
Dr. Spielberg recently joined the FDA. He has been a practitioner and an advocate for personalized medicine in the pediatric setting. He will talk about his past experiences and his current plans at the FDA about personalized medicine.
 
Stephen Spielberg, M.D., Ph.D.
Deputy Commissioner for Medical Products & Tobacco, FDA
 
Introducer: Robert C. Green, M.D., M.P.H.
Associate Director for Research, Partners HealthCare Center for Personalized Genetic Medicine, Division of Genetics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School
 
1:45 p.m.
Personalized Medicine in Academic Medical Centers: A Panel Discussion
 
Several large academic medical centers have new initiatives to implement the principles of personalized medicine at their institutions. We will hear examples of the role of personalized medicine in children’s health care institutions and a cancer center. For personalized medicine to be an important component of medical practice, it is important to educate primary care physicians, other health care professionals and the public about its benefits. We will hear how some institutions are attempting to accomplish this goal.
 
Moderator: Dietrich Stephan, Ph.D.
Founder & CEO, Institute for Individualized Health
 
Howard Jacob, Ph.D.
Dir., Human & Molecular Genetics Center; Warren P. Knowles Chair of Genetics; Prof., Dept. of Physiology & Pediatrics, Medical College of Wisconsin; Vice Chair of Research, Dept. of Pediatrics, Children’s Hospital of Wisconsin
 
Bertram Lubin, M.D.
President & CEO, Children’s Hospital & Research Center Oakland
 
Amy Abernethy, M.D.
Associate Professor of Medicine, Division of Medical Oncology, Department of Medicine, Duke University School of Medicine, Director, Duke Cancer Care Research Program
 
Cynthia Casson Morton, Ph.D.
William Lambert Richardson Professor of Obstetrics, Gynecology and Reproductive Biology and Professor of Pathology, Harvard Medical School; Director of Cytogenetics, Brigham and Women’s Hospital
 
2:55 p.m.
 
Perspectives on Personalized Medicine: A Conversation
 
Brook Byers has been an important advocate for personalized medicine, and his investment firm has made significant investments in a large number of companies that developed an offering of personalized medicine tools and services. GE Healthcare has also made a substantial financial investment by acquiring Clarient, a diagnostics company. Raju will engage Brook and Pascale in a conversation about the business atmosphere for personalized medicine, how each of them is working to make personalized medicine a reality, and what they see in the future. 
 
Raju Kucherlapati, Ph.D.
Paul C. Cabot Professor of Genetics, Professor of Medicine, Harvard Medical School
 
Brook Byers
Partner, Kleiner Perkins Caufield & Byers
 
Pascale Witz
President and CEO, Medical Diagnostics, GE Healthcare
 
3:35 p.m.
Networking Break
 
 
 
4:05 p.m.
Personalized Medicine in Practice: A Panel Discussion
 
Personalized medicine efforts were initiated at academic medical centers, but now there is a significant effort to move personalized medicine to large populations in the U.S. We will hear examples of efforts at the Veteran’s Administration, a large oncology network, and the excitement and challenges of bringing personalized medicine to community practices. 
 
Moderator: Katherine Johansen Taber, Ph.D.
Senior Scientist, Genetics & Molecular Medicine, American Medical Association
 
Ronald Przygodzki, M.D.
Associate Director for Genomic Medicine, Department of Veterans Affairs
 
Arthur Staddon, M.D.
Clinical Professor of Medicine, University of Pennsylvania School of Medicine
 
W. Gregory Feero, M.D., Ph.D.
Sr. Advisor to the Director for Genomic Medicine, NHGRI
 
Lynn Dowling
Executive Director, Genomic Medicine Institute, El Camino Hospital
 
5:15-6:30 p.m.
Reception at Elements Café
 
 
 
Conference Program     Thursday, November 10, 2011
 
7:00 a.m.
Registration & Continental Breakfast
 
 
 
 
8:00 a.m.
Public Policy: A Panel Discussion
 
It is well recognized that changes in public policy and support from policy makers is critical to advancing personalized medicine. This discussion will involve several individuals who are directly involved in helping direct policy discussions in Washington, DC and in trade associations representing many industries and companies around the country.
 
Moderator: Amy Miller, Ph.D.
Vice President, Public Policy, Personalized Medicine Coalition

Mary Pendergast, J.D.
President, Pendergast Consulting
 
Randy Burkholder
Deputy Vice President, Pharmaceutical Research and Manufacturers of America (PhRMA)
 
Andrew Fish
Executive Director, AdvaMedDx
 
9:00 a.m.
Pfizer’s Crizotinib Development – Strategy & Execution
 
In August 2011, two new personalized medicine cancer drugs were approved by the FDA. One is XALKORI®, a drug for a subset of non small cell lung cancer patients, developed by Pfizer in collaboration with Abbott Molecular.  We will hear about how the two companies decided to collaborate, how a companion diagnostic became an important component of drug development and what such collaboration means for the future of targeted therapies in cancer.
 
Moderator: Deborah Dunsire, M.D.
President & CEO, Millennium: The Takeda Oncology Company
 
Hakan Sakul, Ph.D.
Executive Director and Head of Diagnostics, Worldwide R&D, Clinical Research & Precision Medicine, Pfizer, Inc.
 
D. Stafford O’Kelly
President, Abbott Molecular
 
9:45 a.m.
Networking Break
 
 
10:15 a.m.
The Impact of the $1,000 Genome: A Panel Discussion
 
In 2001, when the draft genome sequence was published, it was estimated that the cost of sequencing a single human genome was $2 to $3 Billion. The last ten years have seen a revolution in new technologies that are promising human genome sequencing for $1,000 or less. This panel will discuss the drivers in reducing the cost of sequencing, how the large data sets that are generated are being handled, and how it is affecting the lives of ordinary individuals.
 
Moderator: Heidi L. Rehm, Ph.D., FACMG
Director, Laboratory for Molecular Medicine, Partners HealthCare Center for Personalized Genetic Medicine, Assistant Professor of Pathology, Brigham and Women’s Hospital & Harvard Medical School
 
Kevin Davies, Ph.D.
Editor-in-Chief, Bio-IT World
 
Michael Pellini, M.D.
President & CEO, Foundation Medicine
 
Gad Getz, Ph.D.
Manager, Computational Biology, Broad Institute
 
Samuel (Sandy) Aronson, ALM, MA
Executive Director of IT, Partners HealthCare Center for Personalized Genetic Medicine
 
11:25 a.m.
AACR Cancer Progress Report: 40 Years of Cancer Research and the Role of Personalized Medicine in Cancer
 
Anna Barker, Ph.D.
Professor and Director, Transformative Healthcare Networks, Co-Director, Complex Adaptive Systems Initiative, Arizona State University
 
 
11:30 a.m.
Keynote: Personalized Medicine in Practice: An Access for all Patients
 
France has made a significant commitment to bringing personalized medicine into cancer care. Professor Calvo will provide a European perspective with special emphasis on France and how the lessons they have learned may be applicable to the rest of the world.
 
Prof. Fabien Calvo, M.D., Ph.D.
Deputy General Director and Director of Research Programs, Institut National du Cancer (INCa), France
 
Introducer: Bruce Johnson, M.D.
Director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Professor of Medicine, Harvard Medical School
 
12:00 p.m.
 
Bag Lunch
 
Open seating
1:00 p.m.
Genetic Test Offerings to the American Population: A Panel Discussion
 
In 2010, several pharmacy benefit managers and pharmacies began to offer genetic testing services to their patients. This offering has the potential to impact tens of millions of people in the United States. This panel will review how these companies made a decision to make personalized medicine an important component of their business plan, how that plan was implemented and how the business is growing. We will also hear payer and analytical perspectives.
 
Moderator: Troyen Brennan, M.D., M.P.H.
Executive VP & CMO, CVS Caremark
 
Glen Stettin, M.D.
CMO, Medco
 
Matthew Zubiller
Vice President, Decision Management, McKesson Health Solutions
 
Louis Hochheiser, M.D.
Vice President & Chief Medical Leader, Humana, Inc.
 
Partner, Health Advances LLC
2:15 p.m.
Interactive Case Study on Business Strategies for Personalized Medicine
 
Case:
Gene Sequencing: Staking a Position in an Expanding Industry
 
For the past two years, our conference has provided a unique feature in the form of a case study prepared by the Harvard Business School that deals with an aspect of personalized medicine. Continuing this tradition, Professor Hamermesh and Ms. Aspinall will present a case study on the business of advancing technologies for DNA sequencing.
 
Moderators:
Richard Hamermesh, D.B.A.
MBA Class of 1961 Professor of Management Practice, Harvard Business School
 
Mara Aspinall
President, Ventana Medical Systems
 
Introducer: Gerald J. McDougall
Partner, PricewaterhouseCoopers
3:30 p.m.
Closing Remarks
Raju Kucherlapati, Ph.D.
Paul C. Cabot Professor of Genetics, Professor of Medicine, Harvard Medical School
 

 

Speakers

Samuel (Sandy) Aronson, ALM, MA
Executive Director of IT, Partners HealthCare Center for Personalized Genetic Medicine
 
Mara Aspinall
President, Ventana Medical Systems
 
Dennis Ausiello, M.D.
Jackson Professor of Clinical Medicine, Harvard Medical School; Chief of Medicine, Massachusetts General Hospital; Chief Scientific Officer, Partners HealthCare
 
Anna Barker, Ph.D.
Professor and Director, Transformative Healthcare Networks, Co-Director, Complex Adaptive Systems Initiative, Arizona State University
 
Randy Burkholder
Deputy Vice President, Pharmaceutical Research and Manufacturers of America (PhRMA)
 
Brook Byers
Partner, Kleiner Perkins Caufield & Byers
 
Prof. Fabien Calvo, M.D., Ph.D.
Deputy General Director and Director of Research Programs, Institut National du Cancer (INCa), France
 
Kevin Davies, Ph.D.
Editor-in-Chief, Bio-IT World
 
Lynn Dowling
Executive Director, Genomic Medicine Institute, El Camino Hospital
 
Deborah Dunsire, M.D.
President & CEO, Millennium: The Takeda Oncology Company
 
Ezekiel Emanuel, M.D., Ph.D.
Vice Provost for Global Initiatives, Diane v.S. Levy and Robert M. Levy University Professor and Chair of the Department of Medical Ethics and Health Policy, University of Pennsylvania
 
W. Gregory Feero, M.D., Ph.D.
Sr. Advisor to the Director for Genomic Medicine, NHGRI
 
Andrew Fish
Executive Director, AdvaMedDx
 
Gad Getz, Ph.D.
Manager, Computational Biology, Broad Institute
 
Richard Hamermesh, D.B.A.
MBA Class of 1961 Professor of Management Practice, Harvard Business School
 
Louis Hochheiser, M.D.
Vice President & Chief Medical Leader, Humana, Inc.
 
Leroy Hood, M.D., Ph.D.
President and Co-Founder, Institute for Systems Biology
 
Howard Jacob, Ph.D.
Dir., Human & Molecular Genetics Center; Warren P. Knowles Chair of Genetics; Prof., Dept. of Physiology & Pediatrics, Medical College of Wisconsin; Vice Chair of Research, Dept. of Pediatrics, Children’s Hospital of Wisconsin
 
David King
President and CEO, LabCorp
 
Raju Kucherlapati, Ph.D.
Paul C. Cabot Professor of Genetics, Professor of Medicine, Harvard Medical School
 
Stephen Little, Ph.D.
Vice President, Personalized Healthcare, QIAGEN
 
Bertram Lubin, M.D.
President & CEO, Children’s Hospital & Research Center Oakland
 
John Mendelsohn, M.D.
Past President, Co-Director of the Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center
 
Amy Miller, Ph.D.
Vice President, Public Policy, Personalized Medicine Coalition

Cynthia Casson Morton, Ph.D.
William Lambert Richardson Professor of Obstetrics, Gynecology and Reproductive Biology and Professor of Pathology, Harvard Medical School; Director of Cytogenetics, Brigham and Women’s Hospital
 
Amanda Murphy, CFA
Healthcare Analyst, Healthcare Research, William Blair & Company
 
John E. Niederhuber, M.D.
Professor of Oncology & Surgery, Johns Hopkins University School of Medicine; Former Director of the National Cancer Institute; Executive VP, Inova Health System; CEO, Inova Translational Medicine Institute
 
D. Stafford O’Kelly
President, Abbott Molecular
 
Michael Pellini, M.D.
President & CEO, Foundation Medicine
 
Mary Pendergast, J.D.
President, Pendergast Consulting
 
Partner, Health Advances LLC
 
Ronald Przygodzki, M.D.
Associate Director for Genomic Medicine, Department of Veterans Affairs
 
Heidi L. Rehm, Ph.D., FACMG
Director, Laboratory for Molecular Medicine, Partners HealthCare Center for Personalized Genetic Medicine, Assistant Professor of Pathology, Brigham and Women’s Hospital & Harvard Medical School
 
Hakan Sakul, Ph.D.
Executive Director and Head of Diagnostics, Worldwide R&D, Clinical Research & Precision Medicine, Pfizer, Inc.
 
Jonathan Sheldon, Ph.D.
Senior Director, Translational Medicine, Oracle Health Sciences Global Business Unit
 
Stephen Spielberg, M.D., Ph.D.
Deputy Commissioner for Medical Products & Tobacco, FDA
 
Arthur Staddon, M.D.
Clinical Professor of Medicine, University of Pennsylvania School of Medicine
 
Glen Stettin, M.D.
CMO, Medco
 
Dietrich Stephan, Ph.D.
Founder & CEO, Institute for Individualized Health
 
Katherine Johansen Taber, Ph.D.
Senior Scientist, Genetics & Molecular Medicine, American Medical Association
 
E. Robert Wassman, M.D.
Chief Genomics Officer, Generation Health
 
Scott Weiss, M.D., M.S.
Scientific Director, Partners HealthCare Center for Personalized Genetic Medicine; Associate Director, Channing Laboratory; Professor of Medicine, Harvard Medical School
 
M. Kathleen Behrens Wilsey, Ph.D.
Founder, KEW Group, LLC
 
Pascale Witz
President and CEO, Medical Diagnostics, GE Healthcare
 
Matthew Zubiller
Vice President, Decision Management, McKesson Health Solutions

Presentations

Opening Remarks

PowerPoint

Scott T. Weiss, M.D., M.S.

Scientific Director, Partners HealthCare Center for Personalized Genetic Medicine

Associate Director, Channing Laboratory

Professor of Medicine, Harvard Medical School

 

Opening Remarks

PowerPoint

Raju Kucherlapati, Ph.D.

Paul C. Cabot Professor of Genetics, Professor of Medicine, Harvard Medical School

 

Keynote: "Is Personalized Medicine a Myth?"

PowerPoint

Ezekiel Emanuel, M.D., Ph.D.

Vice Provost for Global Initiatives, Diane v.S. Levy and Robert M. Levy University Professor and Chair of the Department of Medical Ethics and Health Policy, University of Pennsylvania

 

Talk: "MD Anderson Cancer Center Institute for Personalized Cancer Therapy"

PowerPoint

John Mendelsohn, M.D.

Past President, Co-Director of the Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center

 

Talk: "The Future of Healthcare"

PowerPoint

John E. Niederhuber, M.D.

Professor of Oncology & Surgery, Johns Hopkins University School of Medicine; Former Director the National Cancer Institute; Executive VP, Inova Health System; CEO, Inova Translational Medicine Institute

 

"AACR Cancer Progress Report: 40 Years of Cancer Research and the Role of Personalized Medicine in Cancer"

PowerPoint | Podcast

Anna Barker, Ph.D.

Professor and Director, Transformative Healthcare Networks; Co-Director, Complex Adaptive Systems Initiative, Arizona State University

  

Interactive Case Study on Business Strategies for Personalized Medicine

Case: "Gene Sequencing: Staking a Position in an Expanding Industry"

PowerPoint

Richard Hamermesh, D.B.A.

MBA Class of 1961 Professor of Management Practice, Harvard Business School 

Press

Personalized Medicine and IT

An Interview with Sandy Aronson of the Partners HealthCare Center for Personalized Genetic Medicine

Genome Technology/GenomeWeb

By Matthew Dublin

November 30, 2011

 

Personalized Medicine and Public Policy

Interviews with Amy Miller of the Personalized Medicine Coalition and Heidi Rehm of the Partners HealthCare Center for Personalized Genetic Medicine

Genome Technology/GenomeWeb

By Matthew Dublin

November 25, 2011

 

The Herman Cain-Inspired "1-100-0" Plan for Personalized Medicine?

Xconomy

By Luke Timmerman

November 14, 2011

 

Personalized Medicine Raises Issues of Cost and Efficacy

Health Care Basics - Blog

By Nancy Finn

November 11, 2011

 

Conference on future of personalized medicine kicks off with a challenge

The Boston Globe - White Coat Notes

By Carolyn Johnson

November 9, 2011

Photos

To view photos from the 2011 conference, click here.

Podcasts

Click on the links below to hear brief podcasts created from conversations between Raju Kucherlapati and a number of conference speakers and organizing committee members in October 2011. 

 

Edward Abrahams, Ph.D., President, Personalized Medicine Coalition

Part 1: The progress of personalized medicine and how the PMC brings together diverse constituencies (2:50)

Part 2: What the PMC has done to educate leaders and advocate for public policy (1:53)

Part 3: Changes needed in the health care system for the implementation of personalized medicine (1:13)

 

Mara Aspinall, President, Ventana Medical Systems

Part 1: The vision of personalized medicine at Ventana Medical Systems (2:35)

 

Troyen Brennan, M.D., M.P.H., Executive Vice President, Chief Medical Officer, CVS Caremark

Part 1: The CVS customer base and genetics (1:38)

Part 2: Why CVS Caremark invested in Generation Health (:51)

Part 3: CVS Caremark's genetic tests - 14 and growing (1:47)

 

Howard Jacob, Ph.D., Professor, Director, Human and Molecular Genetics Center, Medical College of Wisconsin 

Part 1: One boy's story (2:03)

Part 2: Diagnostic Odyssey program (2:09)

Part 3: The drastically falling price of sequencing (1:32)

 

Kristin Ciriello Pothier, Partner, Health Advances

Part 1: Services provided to respond to the needs of the client (2:52)

Part 2: Strategies of personalized medicine in emerging markets (4:34)

Part 3: Significant impediments to personalized medicine (4:09)

 

Hakan Sakul, Ph.D., Executive Director & Head of Diagnostics, WW R&D, Clinical Research & Precision Medicine, Pfizer

Part 1: Pfizer's development of Xalcori for non-small cell lung cancer (2:20)

Part 2: The relevance of personalized medicine to Pfizer and other pharmaceutical companies (1:29)

Part 3: Future paths to drug development (:38)

Supporters

Platinum

CVS Caremark

Millennium: The Takeda Oncology Company

 

Gold

HP

Pfizer

PricewaterhouseCoopers

Siemens

 

Silver

Biogen Idec

bioMerieux

Kleiner Perkins Caufield & Byers

LabCorp

Life Technologies

Oracle

Personalized Medicine Coalition

 

Bronze

Eli Lilly

Endo Pharmaceuticals

GenomeQuest

Genoptix Medical Laboratory

Qiagen

 

Contributing

Aetna

EAC (Enterprise Analysis Corporation)

Johnson & Johnson

McKesson

Third Rock Ventures

Committee

Raju Kucherlapati, Ph.D., Chair
Harvard Medical School
 
Edward Abrahams, Ph.D.
Personalized Medicine Coalition
 
Mara G. Aspinall
Founder, Director and Former CEO, On-Q-ity
 
Anna Barker, M.D.
Former Deputy Director, NCI
Private Consultant
 
Troyan Brennan, M.D., M.P.H.
CVS Caremark
 
Brook Byers
Kleiner Perkins Caufield & Byers
 
Nadine Cohen, Ph.D.
Johnson & Johnson Pharmaceutical Research and Development East Coast and Europe
 
Gregory Downing, Ph.D.
The U.S. Department of Health and Human Services

 
Stephen Eck, M.D., Ph.D.
Astellas Pharma Global Development, Inc.
 
Robert S. Epstein, M.D., M.S.
Medco Health Solutions, Inc.
 
Kathy Giusti
Multiple Myeloma Research Foundation (MMRF)
 
Richard G. Hamermesh, D.B.A.
Harvard Business School
 
Katherine Johansen, Ph.D.
American Medical Association
 
Marcia A. Kean
Feinstein Kean Healthcare
 
Lawrence Lesko, Ph.D., F.C.P.
University of Florida
 
Gerald J. McDougall
PricewaterhouseCoopers
 
Kristin Pothier
Health Advances LLC
 
Lori M. Reilly
PhRMA
 
Hakan Sakul, Ph.D.
Pfizer – Worldwide R&D
 
Sue Siegel
MDV-Mohr Davidow Ventures
 
Scott Weiss, M.D., M.S.                                        
Harvard Medical School
Partners HealthCare Center for Personalized Genetic Medicine
 
M. Kathleen Behrens Wilsey, Ph.D.

KEW Group